• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Friday

    5/27/22 3:28:49 PM ET
    $ACB
    $AERI
    $AGIO
    $ALBO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACB alert in real time by email

     

    During Friday's session, 59 stocks hit new 52-week lows.

    Areas of Significance In Today's 52-Week Lows:

    • Medtronic (NYSE:MDT) is the largest company in terms of market cap to set a new 52-week low this morning.
    • Performance Shipping (NASDAQ:PSHG) was the smallest, in terms of market cap, to set a new 52-week low.
    • Performance Shipping (NASDAQ:PSHG)'s stock came under the most pressure, trading down 63.73% to reach a new 52-week low.
    • Sutro Biopharma (NASDAQ:STRO)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low.

    The following stocks achieved new 52-week lows on Friday:

    • Medtronic (NYSE:MDT) stock drifted down 1.89% on Friday morning to hit a new 52-week low of $96.86.
    • Mirati Therapeutics (NASDAQ:MRTX) stock dropped to a yearly low on Friday of $32.96. Shares traded down 33.54%.
    • Canopy Gwth (NASDAQ:CGC) stock drifted down 15.33% on Friday morning to hit a new 52-week low of $4.60.
    • Xencor (NASDAQ:XNCR) stock set a new 52-week low of $21.78 on Friday, moving up 0.78%.
    • Iovance Biotherapeutics (NASDAQ:IOVA) stock dropped to a yearly low on Friday of $6.75. Shares traded down 54.13%.
    • Agios Pharmaceuticals (NASDAQ:AGIO) shares made a new 52-week low of $18.55 on Friday. The stock was up 1.7% for the day.
    • SpringWorks Therapeutics (NASDAQ:SWTX) stock hit a yearly low of $13.60. The stock was down 37.04% for the day.
    • Nuvation Bio (NYSE:NUVB) shares hit a yearly low of $3.40. The stock was up 1.73% on the session.
    • I-MAB (NASDAQ:IMAB) stock drifted down 24.23% on Friday morning to hit a new 52-week low of $8.24.
    • Instil Bio (NASDAQ:TIL) stock achieved a new 52-week low on Friday morning, hitting $4.34 and moving down 34.55%.
    • AnaptysBio (NASDAQ:ANAB) stock hit a new 52-week low of $18.24. The stock was up 0.58% on the session.
    • Stoke Therapeutics (NASDAQ:STOK) stock drifted up 0.26% on Friday morning to hit a new 52-week low of $11.28.
    • Bicycle Therapeutics (NASDAQ:BCYC) shares were up 0.33% for the day, having made a 52-week low of $14.44.
    • North Atlantic Acq (NASDAQ:NAAC) stock hit a yearly low of $8.69. The stock was up 0.34% for the day.
    • Albireo Pharma (NASDAQ:ALBO) shares set a new yearly low of $19.51 this morning. The stock was up 1.55% on the session.
    • Aurora Cannabis (NASDAQ:ACB) stock drifted down 39.01% on Friday morning to hit a new 52-week low of $1.63.
    • Day One Biopharmaceutical (NASDAQ:DAWN) stock drifted down 1.04% on Friday morning to hit a new 52-week low of $5.44.
    • Fanhua (NASDAQ:FANH) stock achieved a new 52-week low on Friday morning, hitting $5.07 and moving down 7.24%.
    • Aerie Pharmaceuticals (NASDAQ:AERI) shares made a new 52-week low of $5.20 on Friday. The stock was down 3.22% for the day.
    • Rayonier Adv Materials (NYSE:RYAM) stock hit a yearly low of $3.74. The stock was down 3.85% for the day.
    • Fathom Digital Mfg (NYSE:FATH) stock hit $4.81 on Friday morning, setting a new 52-week low for a change of up 1.23%.
    • Dyne Therapeutics (NASDAQ:DYN) stock set a new 52-week low of $4.36 on Friday, moving up 3.49%.
    • Ocular Therapeutix (NASDAQ:OCUL) stock set a new 52-week low of $2.92 on Friday, moving up 2.33%.
    • ESSA Pharma (NASDAQ:EPIX) shares fell to $5.11 on Friday, setting a new 52-week low with a shift of down 1.89%.
    • Macrogenics (NASDAQ:MGNX) stock hit a new 52-week low of $3.27. The stock was up 1.17% on the session.
    • Sutro Biopharma (NASDAQ:STRO) shares moved 0.0% (flat) on Friday to hit a new 52-week low of $4.19, drifting 0.0% (flat).
    • Cryptyde (NASDAQ:TYDEV) stock hit $9.85 on Friday morning, setting a new 52-week low for a change of down 7.94%.
    • Scholar Rock Holding (NASDAQ:SRRK) shares hit a yearly low of $4.57. The stock was up 3.79% on the session.
    • Omeros (NASDAQ:OMER) stock hit a yearly low of $2.40. The stock was up 8.26% for the day.
    • Zenvia (NASDAQ:ZENV) stock drifted down 4.87% on Friday morning to hit a new 52-week low of $3.63.
    • Allakos (NASDAQ:ALLK) shares set a new 52-week low of $2.56. The stock traded up 1.16%.
    • Surface Oncology (NASDAQ:SURF) stock drifted up 0.73% on Friday morning to hit a new 52-week low of $1.70.
    • Equillium (NASDAQ:EQ) shares hit a yearly low of $1.82. The stock was up 0.69% on the session.
    • Epizyme (NASDAQ:EPZM) stock dropped to a yearly low on Friday of $0.42. Shares traded up 2.12%.
    • Anebulo Pharmaceuticals (NASDAQ:ANEB) shares were down 1.34% for the day, having made a 52-week low of $2.94.
    • Sientra (NASDAQ:SIEN) stock drifted down 4.29% on Friday morning to hit a new 52-week low of $0.99.
    • MSP Recovery (NASDAQ:MSPR) shares made a new 52-week low of $2.21 on Friday. The stock was down 12.26% for the day.
    • Key Tronic (NASDAQ:KTCC) shares set a new yearly low of $4.97 this morning. The stock was up 0.49% on the session.
    • Biotricity (NASDAQ:BTCY) stock hit $0.95 on Friday morning, setting a new 52-week low for a change of up 2.62%.
    • Ocean Power Technologies (AMEX:OPTT) shares made a new 52-week low of $0.86 on Friday. The stock was down 2.23% for the day.
    • Brenmiller Energy (NASDAQ:BNRG) stock achieved a new 52-week low on Friday morning, hitting $3.42 and moving down 7.57%.
    • Comera Life Sciences (NASDAQ:CMRA) stock set a new 52-week low of $2.50 on Friday, moving down 17.48%.
    • OKYO Pharma (NASDAQ:OKYO) stock hit $1.92 on Friday morning, setting a new 52-week low for a change of down 5.28%.
    • PhaseBio Pharmaceuticals (NASDAQ:PHAS) stock drifted up 2.95% on Friday morning to hit a new 52-week low of $0.74.
    • Missfresh (NASDAQ:MF) stock dropped to a yearly low on Friday of $0.15. Shares traded down 4.79%.
    • Kala Pharmaceuticals (NASDAQ:KALA) shares made a new 52-week low of $0.34 on Friday. The stock was up 0.81% for the day.
    • Ayala Pharmaceuticals (NASDAQ:AYLA) shares reached a new 52-week low of $1.48 on Friday morning, moving down 11.16%.
    • Gravitas Education (NYSE:GEHI) stock hit a yearly low of $0.62. The stock was down 9.75% for the day.
    • Shineco (NASDAQ:SISI) shares set a new 52-week low of $1.60. The stock traded down 1.23%.
    • ComSovereign Holding (NASDAQ:COMS) shares hit a yearly low of $0.16. The stock was down 3.05% on the session.
    • Windtree Therapeutics (NASDAQ:WINT) stock broke to a new 52-week low of $0.42 on Friday. Shares of the company traded up 1.1%.
    • Performance Shipping (NASDAQ:PSHG) stock hit $0.64 on Friday morning, setting a new 52-week low for a change of down 63.73%.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB
    $AERI
    $AGIO
    $ALBO

    CompanyDatePrice TargetRatingAnalyst
    Equillium Inc.
    $EQ
    4/23/2026$7.00Outperform
    Oppenheimer
    Scholar Rock Holding Corporation
    $SRRK
    4/21/2026$62.00Buy
    Canaccord Genuity
    Agios Pharmaceuticals Inc.
    $AGIO
    4/20/2026$65.00 → $50.00Buy
    H.C. Wainwright
    Equillium Inc.
    $EQ
    4/16/2026$6.00Buy
    B. Riley Securities
    Equillium Inc.
    $EQ
    4/14/2026$6.00Strong Buy
    Raymond James
    MacroGenics Inc.
    $MGNX
    4/10/2026$9.00Neutral → Buy
    B. Riley Securities
    Sutro Biopharma Inc.
    $STRO
    4/7/2026$38.00Outperform
    Leerink Partners
    Equillium Inc.
    $EQ
    4/7/2026$10.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    $AERI
    $AGIO
    $ALBO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Bender Jeremy returned 1,799,031 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/23/26 4:40:56 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/23/26 4:39:50 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO and CFO York Charles N Ii returned 312,025 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/23/26 4:39:05 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Key Tronic Corporation Announces Third Quarter Reporting Date

    SPOKANE VALLEY, Wash., April 23, 2026 (GLOBE NEWSWIRE) -- Key Tronic Corporation (NASDAQ:KTCC), announced today that it plans to report its results for the third quarter of fiscal 2026 after market close on May 5, 2026. Key Tronic will host a conference call to discuss its financial results at 2:00 PM Pacific (5:00 PM Eastern) on May 5, 2026. A broadcast of the conference call will be available at www.keytronic.com under "Investor Relations" or by calling 800-330-6710 or +1-213-279-1505 (Access Code: 8278065). A replay will be available at www.keytronic.com under "Investor Relations". About Key Tronic Key Tronic is a leading contract manufacturer offering value-added design and manufact

    4/23/26 5:53:02 PM ET
    $KTCC
    Electrical Products
    Technology

    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 18 new employees. The awards were made as an inducement material to the new employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 320,900 shares of Dyne's common stock at a per share exercise price equal to the closing price of Dyne's common stock on The Nasdaq

    4/23/26 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

    Pre-randomization Atrioventricular Interval Modulation Therapy ("AVIM Therapy") set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure ("oSBP")97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood pressure, with evidence of improved diastolic function and reverse cardiac remodelingThe BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboratio

    4/23/26 12:00:00 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $ACB
    $AERI
    $AGIO
    $ALBO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $38,700 worth of shares (2,000 units at $19.35), increasing direct ownership by 17% to 13,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/13/26 4:46:19 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Equillium with a new price target

    Oppenheimer initiated coverage of Equillium with a rating of Outperform and set a new price target of $7.00

    4/23/26 7:55:51 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Scholar Rock with a new price target

    Canaccord Genuity initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $62.00

    4/21/26 7:34:59 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright reiterated coverage on Agios Pharma with a new price target

    H.C. Wainwright reiterated coverage of Agios Pharma with a rating of Buy and set a new price target of $50.00 from $65.00 previously

    4/20/26 12:09:42 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TAZVERIK issued to EPIZYME INC

    Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

    8/14/24 4:43:30 AM ET
    $EPZM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    SEC Filings

    View All

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/23/26 4:46:15 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/23/26 4:45:31 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/23/26 4:45:18 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    Leadership Updates

    Live Leadership Updates

    View All

    'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign

    New window bags, improved potency, and sharper pricing arrive at retail Victoria Day long weekend Canopy Growth Corporation ("Canopy Growth", "Canopy" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced a refresh of Tweed, one of Canada's most recognizable cannabis brands, alongside a national summer campaign, "There's a Tweed for That." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423388138/en/The Tweed summer campaign launches over the Victoria Day long weekend, the traditional kickoff to the Canadian summer, spotlighting Tweed's updated portfolio, including three new flower strains and the popular Quickies pre-ro

    4/23/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

    SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. "We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development

    4/20/26 7:00:00 AM ET
    $OMER
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACB
    $AERI
    $AGIO
    $ALBO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocean Power Technologies Inc.

    SC 13G/A - Ocean Power Technologies, Inc. (0001378140) (Subject)

    11/27/24 1:43:24 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    Financials

    Live finance-specific insights

    View All

    Key Tronic Corporation Announces Third Quarter Reporting Date

    SPOKANE VALLEY, Wash., April 23, 2026 (GLOBE NEWSWIRE) -- Key Tronic Corporation (NASDAQ:KTCC), announced today that it plans to report its results for the third quarter of fiscal 2026 after market close on May 5, 2026. Key Tronic will host a conference call to discuss its financial results at 2:00 PM Pacific (5:00 PM Eastern) on May 5, 2026. A broadcast of the conference call will be available at www.keytronic.com under "Investor Relations" or by calling 800-330-6710 or +1-213-279-1505 (Access Code: 8278065). A replay will be available at www.keytronic.com under "Investor Relations". About Key Tronic Key Tronic is a leading contract manufacturer offering value-added design and manufact

    4/23/26 5:53:02 PM ET
    $KTCC
    Electrical Products
    Technology

    RYAM Schedules First Quarter 2026 Earnings Release

    Rayonier Advanced Materials (NYSE:RYAM) plans to release its first quarter 2026 earnings on Tuesday, May 5, 2026, after the market closes. RYAM will host a conference call and live webcast at 9:00 a.m. ET on Wednesday, May 6, 2026, to discuss these results. Supplemental materials and access to the live audio webcast will be available at www.RYAM.com. A replay of this webcast will be archived on the company's website shortly after the call. Investors may listen to the conference call by dialing 800-715-9871 (U.S. & Canada Toll-Free) or +1 (646) 307-1963 (International) and entering Conference ID 3159397. An audio replay of the teleconference will be available one hour after the call en

    4/22/26 4:30:00 PM ET
    $RYAM
    Paper
    Basic Materials

    Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

    NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (

    4/20/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care